So here's what's happening with Hims & Hers Health Inc. (HIMS) on Tuesday: the stock is edging lower in premarket trading. This comes after two pieces of news that investors are weighing against each other. On one hand, the company is expanding its business in a hot area—GLP-1 weight loss treatments. On the other, its chief financial officer is planning to sell a chunk of stock worth nearly $5 million.
Let's start with the CFO sale, because that's the kind of thing that makes investors nervous. A recent filing shows CFO Oluyemi Okupe plans to sell shares worth about $5 million. Now, executives sell stock for all sorts of reasons—maybe they need to buy a house, pay taxes, or diversify their portfolio. But when a CFO sells, especially when the stock has been struggling, people tend to notice. It's not necessarily a red flag, but it's definitely a yellow one that makes you check your mirrors.
This filing comes right after Hims & Hers made a move that should, in theory, be good for business. The company recently broadened access to several GLP-1 drugs from Novo Nordisk (NVO), including Wegovy injections in multiple strengths. They're even planning to add a 7.2 mg dose soon. Patients can also get oral GLP-1 options across several dosage levels, with pricing starting at $149 per month. Providers will determine eligibility based on clinical assessments, but the idea is to make these treatments more accessible through their digital platform.
Here's the interesting part: the platform now includes the newly launched Wegovy pill, which is currently the only FDA-approved oral GLP-1 option for weight management. This is a smart move to meet rising demand for convenient obesity treatments. If you're trying to build a telehealth platform that handles everything from hair loss to weight management, having the only oral GLP-1 option on the market is a pretty good selling point.
What the Charts Are Saying
Now let's look at the technical picture, because the numbers tell a story of their own. At $20.27, the stock is trading 8.4% below its 20-day simple moving average of $22.15, which suggests short-term weakness. It's also 28% below its 100-day moving average of $28.21, indicating a bearish intermediate trend.
The relative strength index (RSI) is sitting at 47.48, which is basically neutral—not oversold, not overbought. But the moving average convergence divergence (MACD) shows a bearish signal, with the MACD at -0.3562 below the signal line of -0.1197. Translation: selling pressure is currently dominating.
Here are the levels traders are watching:
- Key Resistance: $22.15 — This level has historically acted as a barrier for upward movement.
- Key Support: $20.00 — A critical level where buying interest may emerge.
Over the past 12 months, Hims & Hers has seen a decline of 26.79%, reflecting broader challenges in the market. The stock is currently trading near its 52-week low of $13.74, which suggests a challenging environment for recovery. When a stock is near its lows, every piece of news gets magnified—good news might bounce it off the bottom, bad news might push it through.
The Business Behind the Stock
For those who aren't familiar, Hims & Hers launched in 2017 as a telehealth platform that connects patients and healthcare providers. They offer treatment options for everything from erectile dysfunction and hair loss to skin care, mental health, and now weight loss. Their offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements.
The company's recent collaboration with Novo Nordisk to provide FDA-approved GLP-1 medications highlights its commitment to expanding access to innovative health solutions. With more than 2 million subscribers, Hims & Hers is positioned as a leading platform in the consumer health market. The question is whether expanding into GLP-1 treatments can offset the stock's technical weakness and the CFO's planned sale.
What Analysts Think
Hims & Hers Health is slated to provide its next financial update on May 4, 2026 (estimated). Here's what the Street is expecting:
- EPS Estimate: 2 cents (Down from 20 cents)
- Revenue Estimate: $618.44 million (Up from $586.01 million)
- Valuation: P/E of 39.9x (Indicates premium valuation)
The stock carries a Hold Rating with an average price target of $31.69. Recent analyst moves include:
- TD Cowen: Hold (Lowers Target to $23.00) (March 27)
- Leerink Partners: Market Perform (Raises Target to $25.00) (March 16)
- Barclays: Overweight (Raises Target to $29.00) (March 11)
Notice the pattern here? Most analysts are in the Hold/Perform camp, but they're adjusting their price targets. Some are lowering them, some are raising them, but nobody's getting wildly bullish or bearish. It's the kind of consensus that says "wait and see."
ETF Exposure Matters
Here's something retail investors don't always think about: Hims & Hers has meaningful exposure in several small-cap ETFs. This matters because when money flows into or out of these ETFs, the fund managers have to buy or sell the underlying stocks automatically. It's like having a built-in buyer or seller that doesn't care about company fundamentals.
The main ETFs with HIMS exposure are:
Because HIMS carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock. So sometimes the stock moves not because of anything Hims & Hers did, but because someone decided to put money into small-cap growth ETFs.
Bottom Line
As of Tuesday's premarket, Hims & Hers Health shares were down 2.10% at $19.90. The stock is caught between expansion into a promising new treatment category and some concerning technical signals, topped off with a CFO who wants to sell $5 million worth of shares.
The GLP-1 expansion makes business sense—it's a growing market, and Hims & Hers is making these treatments more accessible. But the stock's technical picture shows weakness, and analysts aren't exactly pounding the table. Add in the ETF exposure that can create mechanical buying or selling pressure, and you've got a stock that's reacting to multiple forces at once.
For investors, the question is whether the GLP-1 opportunity is big enough to overcome the technical headwinds and executive selling. The company's May earnings report might provide some answers, but until then, the stock looks like it's searching for direction while sitting near its yearly lows.
.jpeg)
